Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-mdm2 | 10 | 2024 | 26 | 5.100 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 72 | 3.090 |
Why?
|
| Molecular Targeted Therapy | 7 | 2024 | 36 | 2.190 |
Why?
|
| NFATC Transcription Factors | 4 | 2020 | 12 | 2.070 |
Why?
|
| Neoplasms | 4 | 2024 | 99 | 1.740 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 30 | 1.660 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 5 | 1.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 55 | 0.990 |
Why?
|
| Animals | 14 | 2024 | 1817 | 0.860 |
Why?
|
| Humans | 19 | 2024 | 5485 | 0.730 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 175 | 0.730 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 26 | 0.730 |
Why?
|
| Mice | 10 | 2022 | 719 | 0.720 |
Why?
|
| Medulloblastoma | 1 | 2020 | 2 | 0.700 |
Why?
|
| Indoles | 1 | 2020 | 8 | 0.700 |
Why?
|
| Glioblastoma | 1 | 2020 | 7 | 0.700 |
Why?
|
| Pyridines | 1 | 2020 | 24 | 0.690 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 9 | 0.650 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 17 | 0.640 |
Why?
|
| Triterpenes | 1 | 2018 | 3 | 0.610 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 16 | 0.610 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 21 | 0.600 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2024 | 11 | 0.550 |
Why?
|
| Choice Behavior | 1 | 2016 | 11 | 0.550 |
Why?
|
| Mass Media | 1 | 2016 | 2 | 0.540 |
Why?
|
| Internationality | 1 | 2016 | 6 | 0.540 |
Why?
|
| Datasets as Topic | 1 | 2016 | 8 | 0.540 |
Why?
|
| Politics | 1 | 2016 | 2 | 0.540 |
Why?
|
| Space Perception | 1 | 2016 | 21 | 0.540 |
Why?
|
| Evoked Potentials, Visual | 1 | 2016 | 20 | 0.540 |
Why?
|
| Brain Mapping | 1 | 2016 | 78 | 0.520 |
Why?
|
| Attention | 1 | 2016 | 77 | 0.500 |
Why?
|
| Protein Binding | 4 | 2024 | 118 | 0.400 |
Why?
|
| Apoptosis | 4 | 2020 | 55 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 34 | 0.380 |
Why?
|
| Benzopyrans | 2 | 2024 | 11 | 0.380 |
Why?
|
| Estrogen Receptor beta | 2 | 2024 | 24 | 0.370 |
Why?
|
| Neuroblastoma | 2 | 2020 | 12 | 0.350 |
Why?
|
| Signal Transduction | 4 | 2023 | 225 | 0.350 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2018 | 14 | 0.350 |
Why?
|
| Female | 8 | 2020 | 2816 | 0.340 |
Why?
|
| Mice, Nude | 2 | 2020 | 24 | 0.330 |
Why?
|
| Prognosis | 2 | 2019 | 59 | 0.320 |
Why?
|
| Drug Discovery | 2 | 2020 | 17 | 0.320 |
Why?
|
| Cell Movement | 2 | 2020 | 64 | 0.320 |
Why?
|
| Male | 6 | 2020 | 2770 | 0.300 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 242 | 0.270 |
Why?
|
| Splicing Factor U2AF | 1 | 2024 | 2 | 0.230 |
Why?
|
| Alternative Splicing | 1 | 2024 | 5 | 0.230 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2023 | 3 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2023 | 9 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 14 | 0.220 |
Why?
|
| Inflammation | 2 | 2020 | 59 | 0.200 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 35 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2021 | 120 | 0.190 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 50 | 0.190 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 2 | 0.190 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2021 | 4 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 6 | 0.190 |
Why?
|
| Rats | 2 | 2019 | 251 | 0.190 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 2 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 2 | 0.180 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 3 | 0.180 |
Why?
|
| Collagen | 1 | 2021 | 34 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2021 | 3 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 11 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 30 | 0.180 |
Why?
|
| Glioma | 1 | 2021 | 10 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 19 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 2 | 0.180 |
Why?
|
| Urea | 1 | 2020 | 5 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 31 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 2 | 0.180 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2020 | 2 | 0.180 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 5 | 0.180 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 7 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 16 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 9 | 0.170 |
Why?
|
| Lung | 1 | 2020 | 42 | 0.170 |
Why?
|
| Quality of Life | 1 | 2021 | 117 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2019 | 2 | 0.170 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 2 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 6 | 0.170 |
Why?
|
| Lupus Nephritis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2019 | 11 | 0.170 |
Why?
|
| Kidney Diseases | 1 | 2019 | 11 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 13 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 10 | 0.160 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 6 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 9 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2019 | 7 | 0.160 |
Why?
|
| Biomarkers | 1 | 2019 | 87 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 33 | 0.160 |
Why?
|
| Biliary Tract | 1 | 2019 | 5 | 0.160 |
Why?
|
| Descemet Membrane | 1 | 2018 | 1 | 0.160 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 1 | 0.160 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2018 | 1 | 0.160 |
Why?
|
| Models, Molecular | 1 | 2019 | 87 | 0.160 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2019 | 14 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2018 | 5 | 0.160 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 7 | 0.160 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 27 | 0.160 |
Why?
|
| Calcineurin | 1 | 2018 | 11 | 0.160 |
Why?
|
| RING Finger Domains | 1 | 2018 | 2 | 0.150 |
Why?
|
| Diarrhea | 1 | 2019 | 23 | 0.150 |
Why?
|
| Elastic Modulus | 1 | 2018 | 32 | 0.150 |
Why?
|
| Proteolysis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 14 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 19 | 0.150 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2018 | 2 | 0.150 |
Why?
|
| Neutrophil Infiltration | 1 | 2018 | 3 | 0.150 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 4 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 5 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2018 | 8 | 0.150 |
Why?
|
| Dementia | 1 | 2019 | 78 | 0.150 |
Why?
|
| Obesity | 1 | 2019 | 118 | 0.150 |
Why?
|
| Middle Aged | 2 | 2020 | 1100 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 27 | 0.150 |
Why?
|
| Fourier Analysis | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hostility | 1 | 2016 | 3 | 0.140 |
Why?
|
| Government | 1 | 2016 | 2 | 0.140 |
Why?
|
| Time Factors | 1 | 2016 | 176 | 0.130 |
Why?
|
| Visual Fields | 1 | 2016 | 67 | 0.130 |
Why?
|
| Photic Stimulation | 1 | 2016 | 148 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 107 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2016 | 134 | 0.120 |
Why?
|
| Adolescent | 1 | 2016 | 806 | 0.100 |
Why?
|
| Young Adult | 1 | 2016 | 852 | 0.100 |
Why?
|
| Neutrophils | 2 | 2020 | 19 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 195 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 13 | 0.060 |
Why?
|
| Binding Sites | 1 | 2024 | 69 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 8 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 6 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2022 | 30 | 0.050 |
Why?
|
| Prolyl Hydroxylases | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 7 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 12 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 8 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 14 | 0.050 |
Why?
|
| CCCTC-Binding Factor | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2021 | 3 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 4 | 0.050 |
Why?
|
| RNA, Untranslated | 1 | 2021 | 6 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2021 | 4 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 27 | 0.050 |
Why?
|
| Cities | 1 | 2021 | 8 | 0.050 |
Why?
|
| China | 1 | 2021 | 28 | 0.050 |
Why?
|
| Rural Population | 1 | 2021 | 10 | 0.050 |
Why?
|
| Urban Population | 1 | 2021 | 18 | 0.050 |
Why?
|
| Genomics | 1 | 2021 | 44 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 30 | 0.040 |
Why?
|
| Drug Design | 1 | 2020 | 16 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 44 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 30 | 0.040 |
Why?
|
| Metaplasia | 1 | 2020 | 6 | 0.040 |
Why?
|
| Personality Disorders | 1 | 2021 | 38 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Pneumonia | 1 | 2020 | 20 | 0.040 |
Why?
|
| Stem Cells | 1 | 2020 | 33 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 24 | 0.040 |
Why?
|
| Collagen Type VIII | 1 | 2018 | 1 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 2018 | 2 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 26 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2019 | 31 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cell Count | 1 | 2018 | 33 | 0.040 |
Why?
|
| Microscopy, Atomic Force | 1 | 2018 | 37 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 49 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2018 | 2 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 22 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 18 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 28 | 0.040 |
Why?
|
| Estrogens | 1 | 2018 | 21 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 9 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 176 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2018 | 143 | 0.040 |
Why?
|
| Child | 1 | 2020 | 657 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 860 | 0.030 |
Why?
|
| Adult | 1 | 2020 | 1687 | 0.030 |
Why?
|